Literature DB >> 3978021

Coumarin 7-hydroxylase activity in human liver microsomes. Properties of the enzyme and interspecies comparisons.

O Pelkonen, E A Sotaniemi, J T Ahokas.   

Abstract

Coumarin 7-hydroxylation and other cytochrome P-450-associated enzyme activities were studied in human liver biopsy homogenates and compared with activities in livers of other species. Coumarin 7-hydroxylation is extraordinarily active in human liver biopsy samples in vitro. Activity is lower in mouse, rabbit or guinea pig liver and essentially absent in rat liver. Cytochrome P-450 content and other associated enzyme activities were higher in animals. Coumarin 7-hydroxylation is induced by phenobarbitone in mouse liver, but no significant increase was seen in human or rat liver after exposure to inducers. Correlations amongst coumarin 7-hydroxylase, aryl hydrocarbon hydroxylase, 7-ethoxycoumarin O-deethylase and cytochrome P-450 are statistically significant (r values from 0.56 to 0.73), but do not permit the conclusion, that the same P-450 form catalyzes all the reactions studied. The correlations between coumarin hydroxylation and antipyrine half-life or clearance are statistically significant, but not good enough for predictive purposes. Coumarin 7-hydroxylase in human liver is inhibited by alpha-naphthoflavone, SKF 525A, metyrapone and aniline.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3978021      PMCID: PMC1463777          DOI: 10.1111/j.1365-2125.1985.tb02613.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  34 in total

1.  A spectrofluorimetric study of the 7-hydroxylation of coumarin by liver microsomes.

Authors:  P J Creaven; D V Parke; R T Williams
Journal:  Biochem J       Date:  1965-08       Impact factor: 3.857

2.  Oxidative drug metabolism in human liver microsomes.

Authors:  E B Nelson; P P Raj; K J Belfi; B S Masters
Journal:  J Pharmacol Exp Ther       Date:  1971-09       Impact factor: 4.030

3.  Substrate-inducible microsomal aryl hydroxylase in mammalian cell culture. I. Assay and properties of induced enzyme.

Authors:  D W Nebert; H V Gelboin
Journal:  J Biol Chem       Date:  1968-12-10       Impact factor: 5.157

4.  Pharmacological implications of microsomal enzyme induction.

Authors:  A H Conney
Journal:  Pharmacol Rev       Date:  1967-09       Impact factor: 25.468

5.  Metabolism of coumarin in man.

Authors:  W H Shilling; R F Crampton; R C Longland
Journal:  Nature       Date:  1969-02-15       Impact factor: 49.962

6.  The influence of phenobarbital on the turnover of hepatic microsomal cytochrome b5 and cytochrome P-450 hemes in the rat.

Authors:  H Greim; J B Schenkman; M Klotzbücher; H Remmer
Journal:  Biochim Biophys Acta       Date:  1970-01-27

7.  Metabolism of coumarin and 4-methylcoumarin by rat-liver microsomes.

Authors:  P A Gibbs; K Janakidevi; G Feuer
Journal:  Can J Biochem       Date:  1971-02

8.  Rapid gas-liquid chromatographic estimation of antipyrine in plasma.

Authors:  L F Prescott; K K Adjepon-Yamoah; E Roberts
Journal:  J Pharm Pharmacol       Date:  1973-03       Impact factor: 3.765

9.  Determination of drug metabolizing enzymes in needle biopsies of human liver.

Authors:  B Schoene; R A Fleischmann; H Remmer; H F von Oldershausen
Journal:  Eur J Clin Pharmacol       Date:  1972-03       Impact factor: 2.953

10.  Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes.

Authors:  P P Wang; P Beaune; L S Kaminsky; G A Dannan; F F Kadlubar; D Larrey; F P Guengerich
Journal:  Biochemistry       Date:  1983-11-08       Impact factor: 3.162

View more
  14 in total

1.  Effect of enzyme induction on bioavailability of hetacillin in patients treated with anticonvulsants and chlorpromazine.

Authors:  P Galanopoulou; C Karageorgiou; K Dimakopoulou
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jan-Mar       Impact factor: 2.441

2.  Human and mouse liver coumarin 7-hydroxylases do not metabolize warfarin in vitro.

Authors:  P Honkakoski; P Arvela; R Juvonen; M A Lang; M Kairaluoma; O Pelkonen
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

3.  Long-Term Engineered Cultures of Primary Mouse Hepatocytes for Strain and Species Comparison Studies During Drug Development.

Authors:  Brenton R Ware; Grace E Brown; Valerie Y Soldatow; Edward L LeCluyse; Salman R Khetani
Journal:  Gene Expr       Date:  2019-07-24

4.  Comparison of CYP2A6 catalytic activity on coumarin 7-hydroxylation in human and monkey liver microsomes.

Authors:  Y Li; N Y Li; E M Sellers
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Oct-Dec       Impact factor: 2.441

5.  Interindividual variability of coumarin 7-hydroxylation in a Turkish population.

Authors:  M Iscan; H Rostami; M Iscan; T Güray; O Pelkonen; A Rautio
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

6.  Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity.

Authors:  J S Miles; A W McLaren; L M Forrester; M J Glancey; M A Lang; C R Wolf
Journal:  Biochem J       Date:  1990-04-15       Impact factor: 3.857

Review 7.  Activation mechanisms to chemical toxicity.

Authors:  D V Parke
Journal:  Arch Toxicol       Date:  1987       Impact factor: 5.153

8.  Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP 2A5 and human CYP 2A6.

Authors:  T Kinonen; M Pasanen; J Gynther; A Poso; T Järvinen; E Alhava; R O Juvonen
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

9.  A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles.

Authors:  P Fernandez-Salguero; S M Hoffman; S Cholerton; H Mohrenweiser; H Raunio; A Rautio; O Pelkonen; J D Huang; W E Evans; J R Idle
Journal:  Am J Hum Genet       Date:  1995-09       Impact factor: 11.025

10.  Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man.

Authors:  D Sesardic; A R Boobis; B P Murray; S Murray; J Segura; R de la Torre; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.